Company intelligence / Profile preview

Vetbiolix

Ownership: Private
Development stage: Phase 2

Overview

Positive results reported from Proof of Concept study with VBX-1000 (previously MIV-701) and from Osteoarthritis Clinical Study in Dogs. Currently running two open-label, multicenter Proof-of-Concept clinical studies for VBX-3000 in dogs and cats with gut motility disorders, with final results expected by Q2-2025[5].

Therapeutic areas: GastroenterologyRheumatologyInfectious Diseases
Modalities: Small molecules
Industry: Veterinary

Drug pipeline

3 assets

VBX-1000

Phase 2

Indications: Periodontal disease

2 more assets in the full pipeline.

Partnerships

MedivirCan-Fite BioPharmaRaQualia Pharma

Beyond the preview

Go deeper on Vetbiolix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vetbiolix.